In its upcoming report, Astrazeneca (NYSE: AZN) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting a decline of 1% compared to the same period last year. Revenues are forecasted to be $11.94 billion, representing a year-over-year increase of 9.7%. Over the last 30 days, there has been a downward revision of 1.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. While investors usually depend on consensus earnings and revenue estimates to ...